NCT01372384View on ClinicalTrials.gov

A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions

Non-Squamous Non-Small Cell Lung Cancer

Interventions

DRUG

erlotinib [Tarceva]

150 mg orally daily

Trial Locations (9)

1404

Sofia

1431

Sofia

1527

Sofia

1756

Sofia

4004

Plovdiv

5000

Veliko Tarnovo

8000

Stara Zagora

9002

Varna

9010

Varna

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01372384 - A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations | Biotech Hunter | Biotech Hunter